ABBVIE INC.
Market cap $466.6B
$263.93
ABBV
$263.93
-0.01% today
Buy with €1M virtual cash · No real money
ABBVIE INC. (ABBV) is a publicly traded company listed on the XNYS. As of September 18, 2026, Invest's signal rates ABBV a Buy, with the stock up 20% over the past year. You can practice trading ABBV risk-free with €1,000,000 in virtual cash.
Key stats
As of September 18, 2026
Market Cap
$466.6B
Volume
8.0M
52-wk High
$267.47
52-wk Low
$190.75
Day High
$266.34
Day Low
$262.44
P/E (TTM)
74.56
Revenue (TTM)
$64.4B
EPS (TTM)
$3.54
Performance
1M
-0.8%
6M
+28.0%
1Y
+19.5%
Invest signal · ABBV
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
ABBV overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev +13.3%Revenue
$17BEPS (diluted)
$2.03 per shareLatest ABBV news
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
Zacks Investment Research · 8h ago
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 8h ago
Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape
GlobeNewswire Inc. · 1d ago
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
The Motley Fool · 3d ago
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
Zacks Investment Research · 3d ago
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox.
The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Employees
57,000
30-Day Win Rate · ABBV
14 days
10 days
Last 24 sessions
How to practice trading ABBV
- 1
Use the ABBV buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top ABBV traders on Invest
Full leaderboardFrequently asked questions
Is ABBV a good stock to buy right now?
As of September 18, 2026, Invest's signal rates ABBV a Buy, based on its price trend, valuation, and fundamentals (P/E around 74.6), with the stock up 20% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading ABBV risk-free first.
What is ABBVIE INC.'s (ABBV) market cap?
ABBVIE INC. has a market capitalization of approximately $466.6B, on trailing-twelve-month revenue of about $64.4B.
How has ABBV stock performed?
ABBV is up 20% over the past year and up 28% over six months. Its 52-week range runs roughly from $190.75 to $267.47. Past performance doesn't predict future results.
How can I practice trading ABBV for free?
On Invest you get €1,000,000 in virtual cash and can buy ABBV at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare ABBV with peers